Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
==== 1300–1399 ==== Concession Statements (Prescribed Information) Regulations 1993 (S.I. 1993/1300) Gipsy Encampments (City of Hereford) Order 1993 (S.I. 1993/1301) South Wales Police (Amalgamation) (Amendment) (No. 2) Order 1993 (S.I. 1993/1302) Dyfed-Powys Police (Amalgamation) (Amendment) (No. 2) Order 1993 (S.I. 1993/1303) Seed Potatoes (Fees) (Scotland) Regulations 1993 (S.I. 1993/1311) Eastwood and East Kilbride Districts (Busby) Boundaries Amendment Order 1993 (S.I. 1993/1312) Margate Pier and Harbour Revision Order 1992 (SI 1993/1313) Integrated Administration and Control System Regulations 1993 (S.I. 1993/1317) Lewisham and Southwark (London Borough Boundaries) Order 1993 (S.I. 1993/1318) Greater London and Surrey (County and London Borough Boundaries) (No.3) Order 1993 (S.I. 1993/1319) Plant Health (Great Britain) Order 1993 (S.I. 1993/1320) Health and Safety (Fees) Regulations 1993 (S.I. 1993/1321) A500 Newcastle-Under-Lyme to Nantwich Trunk Road (Basford-Hough-Shavington Bypass and Slip Road) Order 1993 (S.I. 1993/1322) A500 Newcastle-Under-Lyme to Nantwich Trunk Road (Basford-Hough-Shavington Bypass) (Detrunking) Order 1993 (S.I. 1993/1323) Post Office (Abolition of Import Restrictions) Regulations 1993 (S.I. 1993/1324) Fishing Vessels (Safety Improvements) (Grants) Scheme 1993 (S.I. 1993/1325) Insurance Companies (Cancellation) Regulations 1993 (S.I. 1993/1327) Diseases of Animals (Therapeutic Substances) (Revocation) Order 1993 (S.I. 1993/1331) Foot-and-Mouth Disease (Sera and Glandular Products) (Revocation) Order 1993 (S.I.
Since most venomous snakes move about during the dawn dusk or night, one may expect more encounters during the early morning or late afternoon, though many species such as the Western Diamondback may be encountered at any time of day and in fact most bites occur during the month of April when both snakes and humans are out and about and encounter one another hiking, in yards, or on pathways. Children playing within short distances of their homes crawl under porches, jump into bushes, pull boards of wood from a pile and are bitten. Most however occur when people handle rattlesnakes. In South Asia, it was previously believed that Indian cobras, common kraits, Russell's viper, and carpet vipers were the most dangerous; other snakes, however, may also cause significant problems in this area of the world.
=== Neuroprotection === Ciclosporin is in a phase II/III (adaptive) clinical study in Europe to determine its ability to ameliorate neuronal cellular damage and reperfusion injury (phase III) in traumatic brain injury. This multi-center study is being organized by NeuroVive Pharma and the European Brain Injury Consortium using NeuroVive's formulation of ciclosporin called Neurostat (also known by its cardioprotection brand name of Ciclomulsion). This formulation uses a lipid emulsion base instead of cremophor and ethanol. NeuroSTAT was compared to Sandimmune in a phase I study and found to be bioequivalent. In this study, NeuroSTAT did not exhibit the anaphylactic and hypersensitivity reactions found in cremophor- and ethanol-based products. Ciclosporin has been investigated as a possible neuroprotective agent in conditions such as traumatic brain injury, and has been shown in animal experiments to reduce brain damage associated with injury. Ciclosporin blocks the formation of the mitochondrial permeability transition pore, which has been found to cause much of the damage associated with head injury and neurodegenerative diseases. Ciclosporin's neuroprotective properties were first discovered in the early 1990s when two researchers (Eskil Elmér and Hiroyuki Uchino) were conducting experiments in cell transplantation. An unintended finding was that cyclosporin A was strongly neuroprotective when it crossed the blood–brain barrier. This same process of mitochondrial destruction through the opening of the MPT pore is implicated in making traumatic brain injuries much worse.
Adult blaschkitis Aquadynia Aquagenic pruritus Biliary pruritus Cholestatic pruritus Drug-induced pruritus Hydroxyethyl starch-induced pruritus Lichen simplex chronicus (neurodermatitis) Prion pruritus Prurigo nodularis Prurigo pigmentosa Prurigo simplex Pruritus ani Pruritus scroti Pruritus vulvae Puncta pruritica (itchy points) Scalp pruritus Senile pruritus Uremic pruritus (renal pruritus)
Sources: en.wikipedia.org
== Spectroscopy == Both the fluorescence excitation and emission spectrums of wild-type EosFP are shifted ~65 nm to the right upon excitation toward the red end of the spectrum. This spectral change is caused by an extension of the chromophore accompanied by a break in the peptide backbone between Phe-61 and His-62 in an irreversible mechanism. The presence of a crisp isosbestic point at 432 nm also suggests an interconversion between two species. An absorption peak at 280 nm is visible due to aromatic amino acids which transfer their excitation energy to the green chromophore. The quantum yield of the green-emitting form of Eos is 0.7. In the red shifted species, there are pronounced vibronic sidebands separate from the main peak at 533 nm and 629 nm in the excitation spectrum and emission spectrum respectively. There is another peak in the red excitation spectrum at 502 nm likely due to FRET excitation of the red fluorophore. The quantum yield of the red-emitting form is 0.55. EosFPs variants show almost no difference in spectroscopic properties, therefore, it is likely that the structural modifications which arise from separation of interfaces have little to no effect on the structure of the fluorophore-binding site.
Also, in the post-war years, communication between English and German scientists was poor. Following the new reports, the method of gas chromatography spread widely and Cremer's work slowly gained more recognition. Cremer and her students continued their work on developing both the methods and theories behind gas chromatography over the next two decades and led to many of contemporary, common use ideas used in gas chromatography. Cremer and her group created the phrase "relative retention time" and how to calculate the peak area through multiplying the peak's height by the width of the peak at half height. Additionally, they demonstrated the relationship between measurement and column temperature and also invented head space analysis.
Apart from several bog bodies, Denmark has also yielded several other mummies, such as the three Borum Eshøj mummies, the Skrydstrup Woman and the Egtved Girl, who were all found inside burial mounds, or tumuli. In 1875, the Borum Eshøj grave mound was uncovered, which had been built around three coffins, which belonged to a middle aged man and woman as well as a man in his early twenties. Through examination, the woman was discovered to be around 50–60 years old. She was found with several artifacts made of bronze, consisting of buttons, a belt plate, and rings, showing she was of higher class. All of the hair had been removed from the skull later when farmers had dug through the casket. Her original hairstyle is unknown. The two men wore kilts, and the younger man wore a sheath which contained a bronze dagger. All three mummies were dated to 1351–1345 BC. The Skrydstrup Woman was unearthed from a tumulus in Southern Jutland, in 1935. Carbon-14 dating showed that she had died around 1300 BC; examination also revealed that she was around 18–19 years old at the time of death, and that she had been buried in the summertime. Her hair had been drawn up in an elaborate hairstyle, which was then covered by a horse hair hairnet made by the sprang technique. She was wearing a blouse and a necklace as well as two golden earrings, showing she was of higher class. The Egtved Girl, dated to 1370 BC, was also found inside a sealed coffin within a tumulus, in 1921. She was wearing a bodice and a skirt, including a belt and bronze bracelets.
Exercising regularly, as exercise increases cellular sugar uptake, which decreases excessive insulin release. Avoiding eating meals or snacks composed entirely of carbohydrates; simultaneously ingest fats and proteins, which have slower rates of absorption; Consistently choosing longer lasting, complex carbohydrates to prevent rapid blood-sugar dips in the event that one does consume a disproportionately large amount of carbohydrates with a meal; Monitoring any effects medication may have on symptoms. Low-carbohydrate diet and/or frequent small meals is the first treatment of this condition. The first important point is to add small meals at the middle of the morning and of the afternoon, when glycemia would start to decrease. If adequate composition of the meal is found, the fall in blood glucose is thus prevented. Patients should avoid rapidly absorbed sugars and thus avoid popular soft drinks rich in glucose or sucrose. They should also be cautious with drinks associating sugar and alcohol, mainly in the fasting state. As it is a short-term ailment, a sugar crash that was not caused by injecting too much insulin does not usually require medical intervention in most people. The most important factors to consider when addressing this issue are the composition and timing of foods. Acute (short-term) low blood sugar symptoms are best treated by consuming small amounts of sweet foods, so as to regain balance in the body's carbohydrate metabolism. Suggestions include sugary foods that are quickly digested, such as:
At Oxford, Charles Fletcher volunteered to find test cases for human trials. Elva Akers, an Oxford woman dying from incurable cancer, agreed to be a test subject for the toxicity of penicillin. On 17 January 1941, he intravenously injected her with 100 mg of penicillin. Her temperature briefly rose, but otherwise she had no ill-effects. Florey reckoned that the fever was caused by pyrogens in the penicillin; these were removed with improved chromatography. Fletcher next identified an Oxford policeman, Albert Alexander, who had a severe facial infection involving streptococci and staphylococci which had developed from a small sore at the corner of his mouth. His whole face, eyes and scalp were swollen to the extent that he had an eye removed to relieve the pain. On 12 February, Fletcher administered 200 mg of penicillin, following by 100 mg doses every three hours. Within a day of being given penicillin, Alexander started to recover; his temperature dropped and discharge from his suppurating wounds declined. By 17 February, his right eye had become normal. However, the researchers did not have enough penicillin to help him to a full recovery. Penicillin was recovered from his urine, but it was not enough. In early March he relapsed, and he died on 15 March. Because of this experience and the difficulty in producing penicillin, Florey changed the focus to treating children, who could be treated with smaller quantities of penicillin. Subsequently, several patients were treated successfully.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.